Clinical Trial Developments: Tuberculosis Study Dosing, Breast Cancer Data & Industry Bias Debate

Clinical research continues to evolve through new patient-dosing milestones, emerging oncology data, and deeper examination of systemic issues within trial design. Recent developments span infectious disease research, breast cancer therapy innovation, and an important conversation about patient bias embedded in clinical trial methodologies.

Key updates reported by Clinical Trial Vanguard highlight how these issues are shaping both scientific progress and broader industry practices.

Phase 2b Tuberculosis Trial Doses First Patient with AlpE

A significant milestone has been reached in tuberculosis research as the first patient has been dosed in a Phase 2b regimen-selection study evaluating alpibectir-ethionamide (AlpE) for drug-susceptible pulmonary tuberculosis. The study is part of the EU-funded UNITE4TB platform and is being conducted across several African clinical sites.

The trial design combines AlpE with rifampicin, pyrazinamide, and ethambutol during the initial treatment phase, followed by continuation therapy with rifampicin and isoniazid. Researchers aim to identify optimized treatment regimens, with study results expected later in the decade.

Further details are available in Phase 2b Tuberculosis Trial Doses First Patient with ALPE.

New Gedatolisib Data from the VIKTORIA-1 Breast Cancer Study

Advancements in oncology are also emerging with new data from the VIKTORIA-1 study evaluating gedatolisib-based therapies in hormone receptor–positive, HER2-negative advanced breast cancer. The investigational pan-PI3K/mTOR inhibitor demonstrated a strong progression-free survival benefit in patients with PIK3CA wild-type disease, an area where current targeted therapies are limited.

The results have generated significant attention, with the therapy’s regulatory application receiving FDA Priority Review and a decision expected in 2026.

Learn more in New Gedatolisib Breast Cancer Data from VIKTORIA-1 Study.

Examining Patient Bias in Clinical Trial Design

Beyond clinical outcomes, the research community is increasingly examining structural biases that influence trial participation and eligibility criteria. One recent analysis highlights how the removal of race-adjusted variables from kidney function calculations revealed disparities in transplant eligibility, exposing broader bias within medical algorithms and clinical research systems.

These findings raise critical questions about how historical assumptions embedded in trial eligibility criteria may inadvertently limit access for certain populations, reinforcing the need for more inclusive research frameworks.

More insights are discussed in How a Single eGFR Change Is Exposing the Clinical Trial Industry’s Embedded Patient Bias Problem.

Emerging Themes Across Clinical Research

Together, these developments highlight several key themes shaping modern clinical trials:

• Continued advancement of therapies targeting infectious diseases and oncology
• Increasing attention to precision medicine and targeted treatment strategies
• Growing awareness of structural bias within clinical research systems

Monitoring these developments provides valuable insight into both the scientific progress and systemic evolution of clinical trial methodologies.